VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IMVT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IMVTImmunovant, Inc.
$33.17$6.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIMVTFinancials

Immunovant, Inc. (IMVT) Income Statement

9Y historyFree accessUpdated daily

Revenue was effectively absent across most of the ten quarters shown, with only $7.1M reported in 2027Q1, while operating margin of -21.6% and net loss of $153.2M in that quarter indicate losses remain driven by development spending rather than commercial scale.

Income StatementBalance SheetCash FlowRatios

IMVT Income Statement

Annual statement

IMVT Income Statement

Immunovant, Inc. (IMVT) annual income statement — 9-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18
Sales/Revenue7.09M000000000
Revenue Growth %----------
Cost of Goods Sold101K00000021K00
COGS % of Revenue----------
Gross Profit6.99M000000-21K00
Gross Margin %98.58%---------
Gross Profit Growth %------100%---
Operating Expenses538.39M532.9M438.15M270.21M208.28M156.03M108.12M59.66M448136.74M
OpEx % of Revenue----------
Selling, General & Admin69.54M76.24M77.23M57.28M48.02M54.23M39.51M11.73M4481.48M
SG&A % of Revenue----------
Research & Development468.85M456.66M360.92M212.93M160.26M101.81M68.6M47.93M25.73M135.26M
R&D % of Revenue----------
Other Operating Expenses0000000000
Operating Income-531.3M-532.9M-438.15M-270.21M-208.28M-156.03M-108.12M-59.68M-450-136.74M
Operating Margin %-7488.36%---------
Operating Income Growth %--21.62%-62.15%-29.74%-33.48%-44.32%-81.17%-100%-
EBITDA-530.92M-532.49M-437.77M-269.98M-208.08M-155.91M-108.05M-59.66M9.55K0
EBITDA Margin %-7483.03%---------
EBITDA Growth %-9.09%-21.64%-62.15%-29.75%-33.47%-44.29%-81.12%---
D&A (Non-Cash Add-back)378K409K377K231K193K126K65K21K10K136.74M
EBIT-510.25M-505.39M-412.95M-258.77M-198.47M-156.81M-108.12M-65.67M-448-136.74M
Net Interest Income20.29M25.33M24.73M24.95M-4.9M00-624.38K00
Interest Income20.29M25.33M24.73M24.95M7.58M0062500
Interest Expense000012.48M00625K00
Other Income/Expense21.05M27.51M25.2M11.44M-2.67M-781K328K-6.61M0116
Pretax Income-510.25M-505.39M-412.95M-258.77M-210.95M-156.81M-107.79M-66.29M-448-136.74M
Pretax Margin %-7191.73%---------
Income Tax-1.29M215K891K567K9K-84K-358K97K00
Effective Tax Rate %0.25%-0.04%-0.22%-0.22%-0%0.05%0.33%-0.15%0%0%
Net Income-508.96M-505.61M-413.84M-259.34M-210.96M-156.73M-107.43M-66.39M-448-136.74M
Net Margin %-7173.52%---------
Net Income Growth %-9.53%-22.17%-59.58%-22.93%-34.6%-45.89%-61.82%-100%-
Net Income (Continuing)-508.96M-505.61M-413.84M-259.34M-210.96M-156.73M-107.43M-66.39M-448-136.74M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)-2.46-2.77-2.73-1.88-1.71-1.43-1.22-1.540.00-13.67
EPS Growth %9.86%-1.47%-45.21%-9.94%-19.58%-17.21%20.78%-100%-
EPS (Basic)--2.77-2.73-1.88-1.71-1.43-1.22-1.540.00-13.68
Diluted Shares Outstanding206.67M182.42M151.57M138.1M123.08M109.68M87.76M43.2M14.38M10M
Basic Shares Outstanding206.67M182.42M151.57M138.1M123.08M109.68M87.76M43.2M14.38M10M
Dividend Payout Ratio----------

Key Metrics

Growth RegimeContracting
ProfitabilityWeak
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Continued operating losses and capital dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2027Q2)

Revenue Absent, Losses Persist Quarterly

Based on reported income statement figures, IMVT generated only $7.1M of revenue in 2027Q1 after recording essentially none across most of the ten quarters shown, leaving top-line growth effectively undefined and unsupportive of any durable commercial trajectory.

The revenue line is too sparse to establish a meaningful growth rate, and the single 2027Q1 data point cannot be annualized or compared against a stable base. The absence of recurring revenue means the company's economics continue to rest on the timing of clinical milestones rather than on demonstrated demand. Investors should monitor whether future revenue, if any, reflects licensing or milestone receipts rather than sustainable product sales.

Fixed R&D Dominates Operating Cost Base

Reported R&D expense ranged from roughly $75M to $142M per quarter across the period, with SG&A comparatively stable near $17M to $26M, indicating that operating losses are driven primarily by development spending rather than overhead.

Because gross profit is negligible, operating income tracks R&D almost entirely, so operating losses widen and narrow with clinical program intensity rather than with any scaling of revenue. The relatively flat SG&A profile suggests limited commercial build-out to date, which is consistent with a pre-commercial stage. This pattern suggests that cost efficiency gains, if any, will depend on R&D phasing rather than on operating leverage in the conventional sense.

Stock Compensation Modest Versus Net Loss

Stock-based compensation of roughly $11M to $18M per quarter is small relative to quarterly net losses of $87M to $153M, so non-cash equity charges do not appear to explain the bulk of reported losses.

The gap between operating loss and net loss is narrow, indicating few non-operating items distorting reported earnings. Reported EPS of -$0.47 in the most recent quarter, ahead of the cited consensus, may reflect timing of expenses rather than structural improvement, and the data alone does not confirm which. Investors should treat the beat cautiously until expense phasing is clarified.

Dilution Risk Given Persistent Losses

With return on equity reported at -64.8% and no debt on the balance sheet, the funding model depends on equity, which may imply future dilution if losses continue at the magnitudes shown in recent quarters.

The bear case centers on the possibility that cumulative losses over the ten-quarter window require repeated equity raises, diluting existing holders before clinical value is realized. The absence of leverage removes solvency pressure in the near term but shifts risk to share count expansion. Monitoring cash runway disclosures and any financing announcements is warranted to assess how much of the thesis depends on future capital access.

IMVT — Frequently Asked Questions

Quick answers to the most common questions about buying IMVT stock.

What was Immunovant, Inc.'s (IMVT) revenue in 2026?

For fiscal year 2026, Immunovant, Inc. (IMVT) reported total revenue of $0.0M.

Is Immunovant, Inc. (IMVT) profitable?

Immunovant, Inc. (IMVT) reported a net loss of $505.6M for the fiscal year ending 2026.